Recent Finacing
Recent Raise
Cyterix Pharmaceutics develops oncology prodrugs using an OncoCYP platform that targets extra‑hepatic cytochrome P450 enzymes overexpressed in tumors, advancing two lead compounds toward IND‑enabling studies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors